EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

By TheStreet Wire 10/18/12 - 05:00 PM EDT

Find out if (TEVA) is in Cramer's Portfolio.

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Teva Pharmaceutical Industries (TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1%. By the end of trading, Teva Pharmaceutical Industries rose 61 cents (1.5%) to $41.41 on average volume. Throughout the day, four million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 2.8 million shares. The stock ranged in a price between $40.91-$41.51 after having opened the day at $41.05 as compared to the previous trading day's close of $40.80. Other companies within the Drugs industry that increased today were: Aegerion Pharmaceuticals (AEGR), up 9.3%, Oxygen Biotherapeutics (OXBT), up 9.1%, AspenBio Pharma (APPY), up 8.8%, and Inovio Pharmaceuticals (INO), up 7.7%.

ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.92 billion and is part of the health care sector. The company has a P/E ratio of 10.9, below the average drugs industry P/E ratio of 11.3 and below the S&P 500 P/E ratio of 17.7. Shares are up 1.1% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

You can view the full Teva Ratings Report.

On the negative front, MannKind Corporation (MNKD), down 24.2%, CytRx Corporation (CYTR), down 19.6%, Peregrine Pharmaceuticals (PPHM), down 10.9%, and Cyclacel Pharmaceuticals (CYCC), down 9.7%, were all laggards within the drugs industry with Biogen Idec (BIIB) being today's drugs industry laggard.

Use our drugs section to find industry-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Find other investment ideas from our top rated ETFs lists.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

For more information on Teva Pharmaceutical Industries Ltd click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.